Pasar al contenido principal
U.S. flag

An official website of the United States government

Here’s how you know

.gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Ante la falta de fondos del gobierno federal, no se actualizará este sitio web y la organización no responderá a transacciones ni consultas hasta que se aprueben los fondos. El Centro Clínico de los Institutos Nacionales de la Salud (el hospital de investigación) permanecerá abierto. Consulte cc.nih.gov (en inglés). 
Infórmese sobre el funcionamiento del gobierno federal y el reinicio de las actividades en opm.gov.
Clinicalinfo.HIV.gov logo.
En afiliación con HIV.gov
Main navigation
  • Inicio
  • Sobre Clinicalinfo
  • Guías
  • Medicamentos
  • Glosario
  • Noticias
  • Recursos
  • Contáctenos
  • Español (Spanish)
  • English
  1. Inicio
  2. Guidelines search

Búsqueda de Guías

  • Perinatal HIV Clinical Guidelines (41)
  • HIV Clinical Guidelines: Adult and Adolescent ARV (36)
  • HIV Clinical Guidelines: Pediatric ARV (36)
  • HIV Clinical Guidelines: Adult and Adolescent Opportunistic Infections (14)
  • HIV Clinical Guidelines: Pediatric Opportunistic Infections (6)
  • Guidance for Caring for People With HIV Displaced by Disasters (2)
Resultados de la búsqueda 61 – 80 de 135
Hepatitis B Virus/HIV Coinfection
… be stopped in people with HBV/HIV (AII).  Before Initiating Tenofovir-Sparing Antiretroviral Regimens People with HIV … should have their HBV status verified before initiating a tenofovir-sparing ARV regimen. See  Optimizing … must be given if the selected ARV regimen does not contain tenofovir (AII).  TAF or TDF are preferred for HBV treatment …
Special Populations: Adolescents and Young Adults With HIV
… regimens. Bictegravir (BIC) coformulated with tenofovir alafenamide (TAF) and emtricitabine (FTC) also has … risk of side effects, such as bone and renal toxicity with tenofovir-based drugs in rapidly growing adolescents. These … peak bone mass, TAF generally should be used instead of tenofovir disoproxil fumarate, because of a greater bone …
Hepatitis C Virus
… DAA regimens. Additionally, the improved safety profile of tenofovir alafenamide (TAF) combined with safety data in the … HBV = hepatitis B virus; HCV = hepatitis C virus; TDF = tenofovir disoproxil fumarate A limited pre-treatment … also increase velpatasvir exposure, which in turn increases tenofovir plasma exposure particularly when administered as …
Special Populations: Early (Acute and Recent) HIV Infection
… ARV regimens is recommended b (AIII): Bictegravir (BIC)/tenofovir alafenamide (TAF)/emtricitabine (FTC) Dolutegravir (DTG) with (TAF or tenofovir disoproxil fumarate [TDF]) c plus (FTC or … of the INSTI genotype. c TAF and TDF are two forms of tenofovir that are approved in the United States. TAF has …
Modifying Antiretroviral Regimens in Children With Sustained Virologic Suppression on Antiretroviral Therapy
… include coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) (Biktarvy) or FTC/TAF … weighing ≥45 kg showed that switching to the FDC DOR/3TC/tenofovir disoproxil (TDF) resulted in maintained … no known mutations associated with resistance to DRV or tenofovir. Must be taken with food. Aged ≥12 years Weighing …
Hepatitis C Virus/HIV Coinfection
… HBV = hepatitis B virus; HCV = hepatitis C virus; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate The treatment of hepatitis C … HBV (positive HBsAg) should receive ART that includes tenofovir alafenamide or tenofovir disoproxil fumarate, or …
Tuberculosis/HIV Coinfection
… or clinically suspected INSTI resistance) (AIII). Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (AIII), tenofovir alafenamide (TAF)/FTC (BIII), or abacavir … DTG dosing (AII). When prescribing either 1HP or 3HP, tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) …
Recognizing and Managing Antiretroviral Treatment Failure
… nucleos(t)ide reverse transcriptase inhibitors, (i.e., tenofovir disoproxil fumarate or tenofovir alafenamide with lamivudine (3TC) or … therapies included abacavir (ABC) and lamivudine (3TC), tenofovir disoproxil fumarate (TDF) and 3TC or TDF and …
Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs
… HIV transmission. 2,90 In addition, newer NRTIs, such as tenofovir, have not been associated with the same degree of … of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse … Stray KM, Park Y, Babusis D, et al. Tenofovir alafenamide (TAF) does not deplete mitochondrial …
Special Populations: Substance Use Disorders and HIV
… with HBV/HIV coinfection unless HBV-active drugs (i.e., tenofovir, entecavir) are included in the regimen. Because … in an urban safety-net HIV clinic reported increases in tenofovir-reactive urine tests and stimulant-negative urine …
Special Populations: Transplantation in People With HIV
… and efficacy of the new regimen before transplant (BIII). Tenofovir alafenamide (TAF) is preferred over tenofovir disoproxil fumarate (TDF) in transplant candidates … = raltegravir; RPV = rilpivirine; RTV = ritonavir; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug …
Special Populations: Women With HIV
… by HIV and some ARV drugs. 19-22 ARV regimens that contain tenofovir disoproxil fumarate (TDF), boosted protease … a 12.3­kg weight gain was recorded among women receiving tenofovir alafenamide (TAF)/emtricitabine (FTC)/DTG compared … Two small studies showed no difference in plasma levels of tenofovir and RAL between pre- and postmenopausal women. …
Overview
… Inhibitors (NRTIs) Abacavir Emtricitabine Lamivudine Tenofovir alafenamide Tenofovir disoproxil fumarate Zidovudine Non-Nucleoside …
Herpes Simplex Virus
… In clinical trials, pre-exposure prophylaxis with vaginal tenofovir gel and oral tenofovir disoproxil fumarate (TDF) or with … Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the …
Drug Name Abbreviations
… saquinavir SQV/r saquinavir/ritonavir T-20 enfuvirtide TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate TFV tenofovir TFV-DP tenofovir diphosphate TMR temsavir TPV …
Atazanavir
… and weighing ≥40 kg if they are not concurrently taking tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), the Panel does not recommend … ATV. Nucleoside reverse transcriptase inhibitors (NRTIs): Tenofovir disoproxil fumarate (TDF) decreases ATV plasma …
Doravirine
… Tablet [Delstrigo] Doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg When using FDC tablets, … with resistance to DOR [Delstrigo] DOR/Lamivudine (3TC)/Tenofovir Disoproxil Fumarate (TDF) Child and Adolescent … in the study used a backbone of lamivudine [3TC] plus tenofovir disoproxil fumarate [TDF]). 3 A similar effect of …
Emtricitabine
… Tablets [Generic] Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg [Biktarvy] Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg [Complera] Emtricitabine 200 …
Darunavir
… Darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg When using FDC tablets, refer to … once daily with food [Symtuza] DRV/COBI/Emtricitabine (FTC)/Tenofovir Alafenamide (TAF) Child and Adolescent (Weighing … no known mutations associated with resistance to DRV or tenofovir. Skin rash, including Stevens-Johnson syndrome and …
Tenofovir AF
… Updated September 30, 2025 Reviewed September 30, 2025 Tenofovir Alafenamide (TAF, Vemlidy) Formulations Tablet: 25 … Tablets [Biktarvy] Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg [Descovy] Emtricitabine 200 …

Paginación

  • Primera página ‹‹
  • Página anterior ‹
  • …
  • Página 2
  • Página 3
  • Página actual 4
  • Página 5
  • Página 6
  • …
  • Siguiente página ›
  • Última página ››

Conéctese con nosotros

Footer menu

  • Inicio
  • Sobre Clinicalinfo
  • Guías
  • Medicamentos
  • Glosario
  • Noticias
  • Recursos
  • Contáctenos
  • Patrocinadores
  • Aviso de no discriminación
  • Accesibilidad
  • El descargo de responsabilidad
  • Mapa del sitio
  • Declaración de privacidad
  • HHS Vulnerability Disclosure

External links

  • HIVinfo.NIH.gov
  • HHS.gov
  • NIH.gov
  • Players & Viewers
  • HHS 508
  • HHS Privacy Policy
  • Whitehouse.gov
  • USA.gov
  • Ley de Acceso a Información

Proporcionado en colaboración con la Oficina de Investigación del SIDA de los NIH.